HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KOSS, L. G. Articles by LESSER, M. Search for Related Content PubMed PubMed Citation Articles by KOSS, L. G. Articles by LESSER, M.

Detection of Endometrial Carcinoma and Hyperplasia in Asymptomatic Women

From the Departments of Pathology, Obstetrics and Gynecology, and Biostatistics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.

Occult endometrial carcinoma is a detectable disease using commercially available sampling devices and cytohistologic techniques. A cohort of 2586 asymptomatic women (98% past the age of 45, 78% Caucasian) was screened. Of these women, 1567 were screened twice, and 187 were screened three times. The prevalence and incidence rates of endometrial carcinoma, as defined in the present study, including four missed cases, were 6.96 per 1000 and 1.71 per 1000 women years, respectively. The prevalence rate was 7.38 per 1000 for Caucasian women and 5.40 per 1000 for women of other races. An epidemiologic evaluation suggested that the onset of menopause past the age of 49 was the only statistically significant risk factor, whereas race, parity, estrogen intake, and obesity, as calculated by the Quetelet index, were not statistically significant. The present study strongly suggests that in asymptomatic women past the age of 50, endometrial hyperplasia does not necessarily precede or accompany the development of endometrial carcinoma. Two distinct mechanisms may be responsible for the onset of endometrial cancer: endometrial hyperplasia occurring in the symptomatic and younger woman; and endometrial adenocarcinoma occurring ab initio in the older patient.

This article has been cited by other articles:

				E. J. Suh-Burgmann and A. Goodman Surveillance for Endometrial Cancer in Women Receiving Tamoxifen Ann Intern Med, July 20, 1999; 131(2): 127 - 135. [Abstract] [Full Text] [PDF]

				A. M. WEBER, J. L. BELINSON, and M. R. PIEDMONTE Risk Factors for Endometrial Hyperplasia and Cancer Among Women With Abnormal Bleeding Obstet. Gynecol., April 1, 1999; 93(4): 594 - 598. [Abstract] [Full Text] [PDF]

				M. Baum and J. Cuzick Adjuvant treatment with tamoxifen BMJ, April 20, 1996; 312(7037): 1036 - 1036. [Full Text]